Imbriani Paola, Schirinzi Tommaso, D'Elia Alessio, Pisani Antonio
.
Acta Biomed. 2017 Aug 23;88(2):190-195. doi: 10.23750/abm.v88i2.5038.
Patients with Parkinson's disease (PD) receiving long-term L-Dopa therapy eventually develop motor complications with unpredictable "on-off" response fluctuations and involuntary movements, leading to progressive disability. Hence, the search for alternative therapeutic choices based on continuous dopaminergic stimulation (CDS) becomes crucial for the treatment of advanced PD. Here, we describe the case of a 70-year-old man with a 9-year history of PD, treated with daytime levodopa-carbidopa intestinal gel (LCIG) and overnight Rotigotine transdermal patch. LCIG monotherapy significantly reduced motor fluctuations and prevented the appearance of unpredictable off periods; concurrently, overnight Rotigotine improved his sleep quality and morning akinesia. Both LCIG and Rotigotine induce CDS, which conceptually mimics physiologic striatal dopamine receptor function. Hence, they both represent a good therapeutic option for the treatment of advanced PD.
接受长期左旋多巴治疗的帕金森病(PD)患者最终会出现运动并发症,伴有不可预测的“开-关”反应波动和不自主运动,导致进行性残疾。因此,寻找基于持续多巴胺能刺激(CDS)的替代治疗选择对于晚期PD的治疗至关重要。在此,我们描述了一名70岁男性患者的病例,该患者有9年的PD病史,接受日间左旋多巴-卡比多巴肠凝胶(LCIG)和夜间罗替戈汀透皮贴剂治疗。LCIG单药治疗显著减少了运动波动,并防止了不可预测的关期出现;同时,夜间使用罗替戈汀改善了他的睡眠质量和晨僵。LCIG和罗替戈汀均诱导CDS,从概念上讲,这模拟了生理性纹状体多巴胺受体功能。因此,它们两者均代表了晚期PD治疗的良好治疗选择。